Name | 2-Chloro-6-methylaniline |
Synonyms | 6-chloro-o-toluidine o-Toluidine, 6-chloro- 2-Amino-3-chlorotoluene 2-CHLORO-6-METHYLANINILE 2-Chloro-6-Methylaninile 2-Chloro-6-methylaniline 2-methyl-6-chloro aniline 2-chloro-6-methylbenzenamine 2-Chloro-6-methyl-phenylamine benzenamine,2-chloro-6-methyl- BENZENEAMINE,2-CHLORO-6-METHYL- benzenamine,2-chloro-6-methyl-(6-cot) |
CAS | 87-63-8 |
EINECS | 201-759-2 |
InChI | InChI=1/C7H8ClN/c1-5-3-2-4-6(8)7(5)9/h2-4H,9H2,1H3 |
InChIKey | WFNLHDJJZSJARK-UHFFFAOYSA-N |
Molecular Formula | C7H8ClN |
Molar Mass | 141.6 |
Density | 1.152g/mLat 25°C(lit.) |
Melting Point | 10-12°C(lit.) |
Boling Point | 215°C(lit.) |
Flash Point | 210°F |
Water Solubility | Immiscible |
Solubility | Chloroform (Slightly), Ethyl Acetate (Slightly) |
Vapor Presure | 0.151mmHg at 25°C |
Appearance | Oil |
Color | Clear Colourless to Pale Purple |
BRN | 774624 |
pKa | 2.51±0.10(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Room Temperature |
Refractive Index | n20/D 1.576(lit.) |
Physical and Chemical Properties | Clear wine-red liquid. |
Use | Used as pharmaceutical, pesticide, dye intermediates |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
UN IDs | UN 3429 6.1/PG 3 |
WGK Germany | 3 |
RTECS | XU5100000 |
TSCA | Yes |
HS Code | 29214300 |
Hazard Class | 6.1 |
Packing Group | III |
NIST chemical information | information provided by: webbook.nist.gov (external link) |
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
Introduction | 2-chloro-6-methylaniline is an important pharmaceutical intermediate for the synthesis of dasatinib. Dasatinib is an oral tyrosine kinase inhibitor developed by Bristol-Myers Squibb. The drug was approved by the FDA in June 2006 for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. |
Use | for pharmaceutical, pesticide, dye intermediate |